69 related articles for article (PubMed ID: 24995672)
1. Roles of Ki-67, p53, transforming growth factor-β and lysyl oxidase in the metastasis of lung cancer.
Araz O; Demirci E; Ucar EY; Calik M; Karaman A; Durur-Subasi I; Orsal E; Subasi M; Daloglu F; Akgun M
Respirology; 2014 Oct; 19(7):1034-9. PubMed ID: 24995672
[TBL] [Abstract][Full Text] [Related]
2. Relationship between primary lesion metabolic parameters and clinical stage in lung cancer.
Sahiner I; Atasever T; Akdemir UO; Ozturk C; Memis L
Rev Esp Med Nucl Imagen Mol; 2013; 32(6):357-63. PubMed ID: 23747221
[TBL] [Abstract][Full Text] [Related]
3. Value of 11C-choline PET/CT for lung cancer diagnosis and the relation between choline metabolism and proliferation of cancer cells.
Li M; Peng Z; Liu Q; Sun J; Yao S; Liu Q
Oncol Rep; 2013 Jan; 29(1):205-11. PubMed ID: 23124523
[TBL] [Abstract][Full Text] [Related]
4. Multifunctional profiling of non-small cell lung cancer using 18F-FDG PET/CT and volume perfusion CT.
Sauter AW; Winterstein S; Spira D; Hetzel J; Schulze M; Mueller M; Pfannenberg C; Claussen CD; Klotz E; Hann von Weyhern C; Horger MS
J Nucl Med; 2012 Apr; 53(4):521-9. PubMed ID: 22414637
[TBL] [Abstract][Full Text] [Related]
5. Metabolic activity on [18f]-fluorodeoxyglucose-positron emission tomography/computed tomography and glucose transporter-1 expression might predict clinical outcomes in patients with limited disease small-cell lung cancer who receive concurrent chemoradiation.
Lee J; Kim JO; Jung CK; Kim YS; Yoo IeR; Choi WH; Jeon EK; Hong SH; Chun SH; Kim SJ; Kim YK; Kang JH
Clin Lung Cancer; 2014 Mar; 15(2):e13-21. PubMed ID: 24368212
[TBL] [Abstract][Full Text] [Related]
6. [Primary tumor SUVmax measured on (18)F-FDG PET-CT correlates with histologic grade and pathologic stage in non-small cell lung cancer].
Zhao SJ; Wu N; Zheng R; Liu Y; Zhang WJ; Liang Y; Zhang H; Li XM
Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):754-7. PubMed ID: 24378097
[TBL] [Abstract][Full Text] [Related]
7. Baseline SUVmax at PET-CT in stage IIIA non-small-cell lung cancer patients undergoing surgery after neoadjuvant therapy: prognostic implication focused on histopathologic subtypes.
Lee HY; Lee KS; Park J; Han J; Kim BT; Kwon OJ; Ahn YC; Ahn MJ; Park K; Kim J; Shim YM
Acad Radiol; 2012 Apr; 19(4):440-5. PubMed ID: 22265854
[TBL] [Abstract][Full Text] [Related]
8. Is (18)F-FDG-PET/CT prognostic factor for survival in patients with small cell lung cancer? Single center experience.
Inal A; Kucukoner M; Kaplan MA; Urakci Z; Nas N; Guven M; Dostbil Z; Altindag S; Isikdogan A
Rev Port Pneumol; 2013; 19(6):260-5. PubMed ID: 23993406
[TBL] [Abstract][Full Text] [Related]
9. Fluorine 18 fluorodeoxyglucose PET/CT volume-based indices in locally advanced non-small cell lung cancer: prediction of residual viable tumor after induction chemotherapy.
Soussan M; Cyrta J; Pouliquen C; Chouahnia K; Orlhac F; Martinod E; Eder V; Morère JF; Buvat I
Radiology; 2014 Sep; 272(3):875-84. PubMed ID: 24761836
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
Vu CC; Matthews R; Kim B; Franceschi D; Bilfinger TV; Moore WH
Nucl Med Commun; 2013 Oct; 34(10):959-63. PubMed ID: 23921784
[TBL] [Abstract][Full Text] [Related]
11. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
van Gool MH; Aukema TS; Schaake EE; Rijna H; Codrington HE; Valdés Olmos RA; Teertstra HJ; van Pel R; Burgers SA; van Tinteren H; Klomp HM
Ann Surg Oncol; 2014 Sep; 21(9):2831-7. PubMed ID: 24845729
[TBL] [Abstract][Full Text] [Related]
12. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
Heusch P; Buchbender C; Köhler J; Nensa F; Beiderwellen K; Kühl H; Lanzman RS; Wittsack HJ; Gomez B; Gauler T; Schuler M; Forsting M; Bockisch A; Antoch G; Heusner TA
Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
[TBL] [Abstract][Full Text] [Related]
13. [F-18]Fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas.
Watanabe K; Nomori H; Ohtsuka T; Naruke T; Ebihara A; Orikasa H; Yamazaki K; Uno K; Kobayashi T; Goya T
Jpn J Clin Oncol; 2006 Jul; 36(7):403-9. PubMed ID: 16782729
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of p53 and Ki-67 antigen expression in surgically treated non-small cell lung cancer: immunocytochemical detection with imprint cytology.
Maddau C; Confortini M; Bisanzi S; Janni A; Montinaro F; Paci E; Pontenani G; Rulli P; Salani A; Zappa M; Benvenuti A; Carozzi FM
Am J Clin Pathol; 2006 Mar; 125(3):425-31. PubMed ID: 16613347
[TBL] [Abstract][Full Text] [Related]
15. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.
Billé A; Pelosi E; Skanjeti A; Arena V; Errico L; Borasio P; Mancini M; Ardissone F
Eur J Cardiothorac Surg; 2009 Sep; 36(3):440-5. PubMed ID: 19464906
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer.
Park SY; Cho A; Yu WS; Lee CY; Lee JG; Kim DJ; Chung KY
J Nucl Med; 2015 Jan; 56(1):45-9. PubMed ID: 25525185
[TBL] [Abstract][Full Text] [Related]
17. Stage migration in planning PET/CT scans in patients due to receive radiotherapy for non-small-cell lung cancer.
Geiger GA; Kim MB; Xanthopoulos EP; Pryma DA; Grover S; Plastaras JP; Langer CJ; Simone CB; Rengan R
Clin Lung Cancer; 2014 Jan; 15(1):79-85. PubMed ID: 24238934
[TBL] [Abstract][Full Text] [Related]
18. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.
Lardinois D; Weder W; Hany TF; Kamel EM; Korom S; Seifert B; von Schulthess GK; Steinert HC
N Engl J Med; 2003 Jun; 348(25):2500-7. PubMed ID: 12815135
[TBL] [Abstract][Full Text] [Related]
19. Expression of Ki-67, Bcl-2, Survivin and p53 Proteins in Patients with Pulmonary Carcinoma.
Halasova E; Adamkov M; Matakova T; Vybohova D; Antosova M; Janickova M; Singliar A; Dobrota D; Jakusova V
Adv Exp Med Biol; 2013; 756():15-21. PubMed ID: 22836614
[TBL] [Abstract][Full Text] [Related]
20. Maspin, VEGF and p53 expression in small biopsies of primary advanced lung cancer and relationship with clinicopathologic parameters.
Bircan A; Bircan S; Kapucuoglu N; Songur N; Ozturk O; Akkaya A
Pathol Oncol Res; 2010 Dec; 16(4):553-61. PubMed ID: 20349288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
